Bromine, bear-claw scratch fasciotomies, and the Eagle effect: Management of group A streptococcal necrotising fasciitis and its association with trauma

The Lancet Infectious Diseases

Volumn 15, Issue 1, 2015, Pages 109-121

  Lamb, Lucy E M ^a   Sriskandan, Shiranee ^a   Tan, Lionel K K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMINE; IMMUNOGLOBULIN; ANTIINFECTIVE AGENT;

BEAR CLAW SCRATCH FASCIOTOMY; DRUG EFFECT; FASCIOTOMY; GAS GANGRENE; GROUP A STREPTOCOCCAL INFECTION; HOSPITAL INFECTION; HUMAN; HYPERBARIC OXYGEN; INFECTION CONTROL; MOLECULAR PATHOLOGY; NECROTIZING FASCIITIS; NONHUMAN; PENETRATING TRAUMA; REVIEW; SCALPEL; SURGICAL TECHNIQUE; WAR; COMPLICATION; DEBRIDEMENT; DRUG THERAPY; FASCIITIS, NECROTIZING; HISTORY; INJURY; ISOLATION AND PURIFICATION; MULTIMODALITY CANCER THERAPY; PROCEDURES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SURGERY;

ANTI-BACTERIAL AGENTS; COMBINED MODALITY THERAPY; DEBRIDEMENT; DRUG THERAPY; FASCIITIS, NECROTIZING; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SURGICAL PROCEDURES, OPERATIVE; WOUNDS AND INJURIES;

EID: 84917708493     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70922-3     Document Type: Review

References (161)

1. Loudon I Necrotising fasciitis, hospital gangrene, and phagedena. Lancet 1994, 344:1416-1419.
2. Meleney FL Hemolytic streptococcus gangrene. Arch Surg 1924, 9:317-364.
3. Wilson B Necrotizing fasciitis. Am Surg 1952, 18:416-431.
4. Jones WHS Hippocrates, vol 1: Airs, waters and places. Epidemics 1 and 3 1923, Harvard University Press, Cambridge.
5. Barnes J The Medical and Surgical History of the Civil War. War of the Rebellion (1861-1865) 1870, Government Printing Office, Washington.
6. Miles AA, Schwabacher H, Cunliffe AC, et al. Hospital infection of war wounds. BMJ 1940, 2:895-900.
7. Hawking F Prevention of gas-gangrene infections by local application of sulphonamide compounds and by sera. BMJ 1941, 1:263-268.
8. Colebrook L, Lowbury EJL, Hurst L The growth and death of wound bacteria in serum, exudate and slough. J Hyg (Lond) 1960, 58:357-366.
9. Jones J Investigation upon the nature, causes and treatment of hospital gangrene as prevailed in the Confederate armies 1861-1865 1871, US Sanitary Commission, New York.
10. Goldsmith M A report on hospital gangrene, erysipelas and pyaemia: as observed in the departments of the Ohio and the Cumberland, with cases appended 1863, Surgeon General USA, Louisville.
11. Billroth T On mutual action of living vegetable and animal cells: a biological study. Translated by Ferninand Adelbert Junker von Langegg 1894, The New Sydenham Society, London.
12. Fleming A On the bacteriology of septic wounds. Lancet 1915, 186:638-643.
13. Meleney FL Hemolytic streptococcus gangrene: importance of early diagnosis and early operation. JAMA 1929, 92:2009-2012.
14. Abraham EP, Chain E, Fletcher CM, et al. Further observations on penicillin. Lancet 1941, 238:177-189.
15. Garrod LP Treatment of war wounds with penicillin. BMJ 1943, 2:755-756.
16. Das DK, Baker MG, Venugopal K Increasing incidence of necrotizing fasciitis in New Zealand: a nationwide study over the period 1990 to 2006. J Infect 2011, 63:429-433.
17. Cartwright K, Logan M, McNulty C, et al. A cluster of cases of streptococcal necrotizing fasciitis in Gloucestershire. Epidemiol Infect 1995, 115:387-397.
18. Kaul R, McGeer A, Low DE, Green K, Schwartz B Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997, 103:18-24.
19. Martin PR, Høiby EA Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990, 22:421-429.
20. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989, 321:1-7.
21. Stevens DL Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995, 1:69-78.
22. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerg Infect Dis 2008, 14:202-209.
23. Lamagni TL, Darenberg J, Luca-Harari B, et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008, 46:2359-2367. the Strep-EURO Study Group.
24. Luca-Harari B, Darenberg J, Neal S, et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2009, 47:1155-1165. the Strep-EURO Study Group.
25. Plainvert C, Doloy A, Loubinoux J, et al. Invasive group A streptococcal infections in adults, France (2006-2010). Clin Microbiol Infect 2012, 18:702-710. the CNR-Strep network.
26. Stockmann C, Ampofo K, Hersh AL, et al. Evolving epidemiologic characteristics of invasive group a streptococcal disease in Utah, 2002-2010. Clin Infect Dis 2012, 55:479-487.
27. Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR Streptococcal myositis. Arch Intern Med 1985, 145:1020-1023.
28. Nothwang J, Ulrich C Necrotising fasciitis-cryptogenic infection following posttraumatic immunopathy?. Arch Orthop Trauma Surg 1998, 118:167-171.
29. Jallali N, Gebru M, Withey S Necrotizing fasciitis of the anterior chest wall following blunt trauma. Eur J Trauma 2004, 30:327-329.
30. Hird B, Byrne K Gangrenous streptococcal myositis: case report. J Trauma 1994, 36:589-591.
31. Heinze S, Püschel K, Tsokos M Necrotizing fasciitis with fatal outcome: a report of two cases. Forensic Sci Med Pathol 2011, 7:278-282.
32. Raffoul T, Fournier B, Lecomte C [Necrotizing fasciitis after a blunt trauma]. Ann Chir Plast Esthet 2010, 55:78-81. (in French).
33. Baker A Group A streptococcal infections in primary care: a case report. Br J Gen Pract 2012, 62:388-389.
34. Jahnson L, Berggren L, Björsell-Ostling E, Bonnerstig J, Holmberg H Streptococcal myositis. Scand J Infect Dis 1992, 24:661-665.
35. Fleming A The action of chemical and physiological antiseptics in a septic wound. Br J Surg 1919, 7:99-129.
36. Murray CK, Hinkle MK, Yun HC History of infections associated with combat-related injuries. J Trauma 2008, 64(suppl 3):S221-S231.
37. Porter R The Greatest Benefit to Mankind: A Medical History of Humanity (The Norton History of Science) 1999, W. W. Norton, New York.
38. Alexander JW The contributions of infection control to a century of surgical progress. Ann Surg 1985, 201:423-428.
39. Trombold JM Gangrene therapy and antisepsis before lister: the civil war contributions of Middleton Goldsmith of Louisville. Am Surg 2011, 77:1138-1143.
40. Quirk WF, Sternbach G Joseph Jones: infection with flesh eating bacteria. J Emerg Med 1996, 14:747-753.
41. Cohen J Hospital gangrene: the scourge of surgeons in the past. Infect Control Hosp Epidemiol 1999, 20:638-640.
42. Koch R Investigations into the Etiology of Traumatic Infective diseases 1880, The New Sydenham Society, London.
43. Blevins SM, Bronze MS Robert Koch and the 'golden age' of bacteriology. Int J Infect Dis 2010, 14:e744-e751.
44. Colebrook L The story of puerperal fever; 1800 to 1950. BMJ 1956, 1:247-252.
45. Wilson LG The early recognition of streptococci as causes of disease. Med Hist 1987, 31:403-414.
46. Fehleisen F Die Aetiologie des Erysipels 1883, T. Fischer, Berlin.
47. Rosenbach FJ Micro-Organismen bei den Wund-Infections-Krankheiten des Menschen 1884, J.F. Bergmann, Wiesbaden.
48. Evans AC Studies on hemolytic streptococci: II. Streptococcus pyogenes. J Bacteriol 1936, 31:611-624.
49. Lancefield RC A serological differentiation of human and other groups of hemolytic streptococci. J Exp Med 1933, 57:571-595.
50. Colebrook L, Kenny M Treatment with prontosil of puerperal infections. Lancet 1936, 228:1319-1322. the members of the HSOFQCSH.
51. Colebrook L, Kenny M Treatment of human puerperal infections, and of experimental infections in mice, with prontosil. Lancet 1936, 227:1279-1286.
52. Long PH Medical progress and medical education during the war. J Am Med Assoc 1946, 130:983-990.
53. Colebrook L Sulphanilamide and wound infections W. BMJ 1940, 2:682.
54. Colebrook L Chemotherapy in relation to war wounds. J R Army Med Corps 1940, 74:197-204.
55. Colebrook L, Gibson T, Todd JP First-Aid treatment of burns and scalds. Br J Ind Med 1944, 1:99-105.
56. Sherman WO Sterilization of wounds, treatment of suppurating wounds and osteomyelitis (Carrel method). Proc R Soc Med 1917, 10(Surg Sect):1-28.
57. Depage A General consideratons as to the treatment of war wounds. Ann Surg 1919, 69:575-588.
58. Hardaway RM 200 years of military surgery. Injury 1999, 30:387-397.
59. McCafferty EL, Lyons C Suppurative fasciitis as the essential feature of hemolytic streptococcus gangrene with notes on fasciotomy and early wound closure as the treatment of choice. Surgery 1948, 24:438-442.
60. Domagk G Twenty-five years of sulfonamide therapy. Ann N Y Acad Sci 1957, 69:380-384.
61. Domagk G Nobel lecture. Further progress in chemotherapy of bacterial infections (accessed Oct 29, 2013). http://www.nobelprize.org/nobel_prizes/medicine/laureates/1939/domagk-lecture.html.
62. Colebrook L Prevention of puerperal sepsis: a call to action. BMJ 1936, 1:1257-1258.
63. Sriskandan S Severe peripartum sepsis. J R Coll Physicians Edinb 2011, 41:339-346.
64. Colebrook LaK M Treatment of human puerperal infections, and of experimental infections in mice, with prontosil. Lancet 1936, 1:1279-1286.
65. Kardos N, Demain AL Penicillin: the medicine with the greatest impact on therapeutic outcomes. Appl Microbiol Biotechnol 2011, 92:677-687.
66. Bud R Penicillin: Triumph and Tragedy 2007, Oxford University Press, Oxford.
67. Jeffrey JS Application of penicillin to war wounds. Br J Surg 1944, 32:124-129.
68. Jeffrey JS, Thomson S Penicillin in battle casualties. BMJ 1944, 2:1-4.
69. Semmelweis IF, Carter KC The Etiology, Concept, and Prophylaxis of Childbed Fever 1983, University of Wisconsin Press, Madison.
70. McKissock W, Wright J, Miles AA Reduction of hospital infection of wounds. A controlled experiment. BMJ 1941, 2:375-377.
71. Steer JA, Lamagni T, Healy B, et al. Guidelines for prevention and control of group A streptococcal infection in acute healthcare and maternity settings in the UK. J Infect 2012, 64:1-18.
72. Eagle H, Musselman AD The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948, 88:99-131.
73. Horn DL, Zabriskie JB, Austrian R, et al. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis 1998, 26:1341-1345.
74. Eagle H Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952, 13:389-399.
75. Stevens DL, Gibbons AE, Bergstrom R, Winn V The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988, 158:23-28.
76. Sriskandan S, McKee A, Hall L, Cohen J Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother 1997, 40:275-277.
77. Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 2014, 59:358-365.
78. Mulla ZD, Leaverton PE, Wiersma ST Invasive group A streptococcal infections in Florida. South Med J 2003, 96:968-973.
79. Zimbelman J, Palmer A, Todd J Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999, 18:1096-1100.
80. Luk EY, Lo JY, Li AZ, et al. Scarlet fever epidemic, Hong Kong, 2011. Emerg Infect Dis 2012, 18:1658-1661.
81. Llewelyn M, Cohen J Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002, 2:156-162.
82. Norrby-Teglund A, Kaul R, Low DE, et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996, 64:5395-5398.
83. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 2006, 58:117-124.
84. Chapel HM International Union of Immunological Societies. Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. Clin Exp Immunol 1999, 118(suppl 1):29-34. the IUIS Committee on Primary Immunodeficiency Disease.
85. Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003, 37:333-340. the StreptIg Study Group.
86. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin Infect Dis 1999, 28:800-807. the The Canadian Streptococcal Study Group.
87. Shah SS, Hall M, Srivastava R, Subramony A, Levin JE Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 2009, 49:1369-1376.
88. Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 2014, 59:851-857.
89. Valiquette L, Low DE, Chow R, McGeer AJ A survey of physician's attitudes regarding management of severe group A streptococcal infections. Scand J Infect Dis 2006, 38:977-982.
90. Jallali N, Withey S, Butler PE Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg 2005, 189:462-466.
91. Hassell M, Fagan P, Carson P, Currie BJ Streptococcal necrotising fasciitis from diverse strains of Streptococcus pyogenes in tropical northern Australia: case series and comparison with the literature. BMC Infect Dis 2004, 4:60.
92. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 1990, 108:847-850.
93. Shupak A, Shoshani O, Goldenberg I, Barzilai A, Moskuna R, Bursztein S Necrotizing fasciitis: an indication for hyperbaric oxygenation therapy?. Surgery 1995, 118:873-878.
94. Massey PR, Sakran JV, Mills AM, et al. Hyperbaric oxygen therapy in necrotizing soft tissue infections. J Surg Res 2012, 177:146-151.
95. Wong CH, Wang YS The diagnosis of necrotizing fasciitis. Curr Opin Infect Dis 2005, 18:101-106.
96. Efstratiou A, George RC, Tanna A, et al. Characterisation of group A streptococci from necrotising fasciitis cases in Gloucestershire, United Kingdom. Adv Exp Med Biol 1997, 418:91-93.
97. Thompson ML, Martin C Management of necrotizing fasciitis infections. Orthopedics 2011, 34:111-115.
98. Svensson LG, Brookstone AJ, Wellsted M Necrotizing fasciitis in contused areas. J Trauma 1985, 25:260-262.
99. Sellers BJ, Woods ML, Morris SE, Saffle JR Necrotizing group A streptococcal infections associated with streptococcal toxic shock syndrome. Am J Surg 1996, 172:523-527. discussion 527-28.
100. Hirose Y, Shibuya H, Okazaki E, et al. Toxic shock-like syndrome with flu-like prodrome: a possible role of 'enhancing tissue focus' for streptococcal toxic shock. J Infect 2001, 42:195-200.
101. Dahl PR, Perniciaro C, Holmkvist KA, O'Connor MI, Gibson LE Fulminant group A streptococcal necrotizing fasciitis: clinical and pathologic findings in 7 patients. J Am Acad Dermatol 2002, 47:489-492.
102. Radovan K, Ilic G, Antovic A, Banovic LK, Miroslav M, Marina D Rapidly fatal necrotizing fasciitis: report of three cases. Rom J Leg Med 2011, 19:95-100.
103. Monnickendam MA, McEvoy MB, Blake WA, et al. Necrotising fasciitis associated with invasive group A streptococcal infections in England and Wales. Adv Exp Med Biol 1997, 418:87-89.
104. Factor SH, Levine OS, Schwartz B, et al. Invasive group A streptococcal disease: risk factors for adults. Emerg Infect Dis 2003, 9:970-977.
105. Hankins CL, Southern S Factors that affect the clinical course of group A beta-haemolytic streptococcal infections of the hand and upper extremity: a retrospective study. Scand J Plast Reconstr Surg Hand Surg 2008, 42:153-157.
106. Nuwayhid ZB, Aronoff DM, Mulla ZD Blunt trauma as a risk factor for group A streptococcal necrotizing fasciitis. Ann Epidemiol 2007, 17:878-881.
107. Imöhl M, van der Linden M, Reinert RR, Ritter K Invasive group A streptococcal disease and association with varicella in Germany, 1996-2009. FEMS Immunol Med Microbiol 2011, 62:101-109.
108. Laupland KB, Davies HD, Low DE, Schwartz B, Green K, McGeer A Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics 2000, 105:E60. the Ontario Group A Streptococcal Study Group.
109. Patel RA, Binns HJ, Shulman ST Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era. J Pediatr 2004, 144:68-74.
110. Cartwright K Group A streptococcal infections in humans. Soc Appl Bacteriol Symp Ser 1997, 26:52S-61S.
111. Weinbren MJ, Perinpanayagam RM Streptococcal necrotising fasciitis. J Infect 1992, 25:299-302.
112. Childers BJ, Potyondy LD, Nachreiner R, et al. Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg 2002, 68:109-116.
113. McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995, 221:558-563. discussion 563-65.
114. Crum NF, Hale BR, Judd SE, Lim ML, Wallace MR A case series of group A streptococcus necrotizing fasciitis in military trainees. Mil Med 2004, 169:373-375.
115. Cruickshank JG, Lightfoot NF, Sugars KH, et al. A large outbreak of streptococcal pyoderma in a military training establishment. J Hyg (Lond) 1982, 89:9-21.
116. Crum NF, Russell KL, Kaplan EL, et al. Pneumonia outbreak associated with group A streptococcus species at a military training facility. Clin Infect Dis 2005, 40:511-518.
117. Wasserzug O, Valinsky L, Klement E, et al. A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis 2009, 48:1213-1219.
118. Schreier AJ, Hockett VE, Seal JR Mass prophylaxis of epidemic streptococcal infections with benzathine penicillin G.I. Experience at a naval training center during the winter of 1955-56. N Engl J Med 1958, 258:1231-1238.
119. Davis J, Schmidt WC Benzathine penicillin G: its effectiveness in the prevention of streptococcal infections in a heavily exposed population. N Engl J Med 1957, 256:339-342.
120. Fujikawa J, Struewing JP, Hyams KC, Kaplan EL, Tupponce AK, Gray GC Oral erythromycin prophylaxis against Streptococcus pyogenes infection in penicillin-allergic military recruits: a randomized clinical trial. J Infect Dis 1992, 166:162-165.
121. Giuliano A, Lewis F, Hadley K, Blaisdell FW Bacteriology of necrotizing fasciitis. Am J Surg 1977, 134:52-57.
122. Morgan MS Diagnosis and management of necrotising fasciitis: a multiparametric approach. J Hosp Infect 2010, 75:249-257.
123. Bernal NP, Latenser BA, Born JM, Liao J Trends in 393 necrotizing acute soft tissue infection patients 2000-2008. Burns 2012, 38:252-260.
124. Keung EZ, Liu X, Nuzhad A, Adams C, Ashley SW, Askari R Immunocompromised status in patients with necrotizing soft-tissue infection. JAMA Surg 2013, 148:419-426.
125. Das DK, Baker MG, Venugopal K Risk factors, microbiological findings and outcomes of necrotizing fasciitis in New Zealand: a retrospective chart review. BMC Infect Dis 2012, 12:348.
126. Yu SN, Kim TH, Lee EJ, et al. Necrotizing fasciitis in three university hospitals in Korea: a change in causative microorganisms and risk factors of mortality during the last decade. Infect Chemother 2013, 45:387-393.
127. Cheng N-C, Yu Y-C, Tai H-C, et al. Recent trend of necrotizing fasciitis in Taiwan: focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis. Clin Infect Dis 2012, 55:930-939.
128. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445-1453.
129. Murray CK Epidemiology of infections associated with combat-related injuries in Iraq and Afghanistan. J Trauma 2008, 64(suppl 3):S232-S238.
130. Fournier JA Jean-Alfred Fournier 1832-1914. Gangrène foudroyante de la verge (overwhelming gangrene). Sem Med 1883. Dis Colon Rectum 1988, 31:984-988.
131. Eke N Fournier's gangrene: a review of 1726 cases. Br J Surg 2000, 87:718-728.
132. Bjurlin MA, O'Grady T, Kim DY, et al. Causative pathogens, antibiotic sensitivity, resistance patterns, and severity in a contemporary series of Fournier's gangrene. Urology 2013, 81:752-758.
133. MacLennan JD The histotoxic clostridial infections of man. Bacteriol Rev 1962, 26:177-276.
134. Thoresby FP, Watts JC Gas gangrene of the high-velocity missile wound. Br J Surg 1967, 54:25-29.
135. Stevens DL, Aldape MJ, Bryant AE Life-threatening clostridial infections. Anaerobe 2012, 18:254-259.
136. Sharma AK, Pangburn MK Localization by site-directed mutagenesis of the site in human complement factor H that binds to Streptococcus pyogenes M protein. Infect Immun 1997, 65:484-487.
137. Cleary PP, Prahbu U, Dale JB, Wexler DE, Handley J Streptococcal C5a peptidase is a highly specific endopeptidase. Infect Immun 1992, 60:5219-5223.
138. Nelson DC, Garbe J, Collin M Cysteine proteinase SpeB from Streptococcus pyogenes - a potent modifier of immunologically important host and bacterial proteins. Biol Chem 2011, 392:1077-1088.
139. Lukomski S, Montgomery CA, Rurangirwa J, et al. Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice. Infect Immun 1999, 67:1779-1788.
140. Akesson P, Sjöholm AG, Björck L Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J Biol Chem 1996, 271:1081-1088.
141. Sumby P, Barbian KD, Gardner DJ, et al. Extracellular deoxyribonuclease made by group A streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc Natl Acad Sci USA 2005, 102:1679-1684.
142. von Pawel-Rammingen U, Johansson BP, Björck L IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 2002, 21:1607-1615.
143. Turner CE, Kurupati P, Jones MD, Edwards RJ, Sriskandan S Emerging role of the interleukin-8 cleaving enzyme SpyCEP in clinical Streptococcus pyogenes infection. J Infect Dis 2009, 200:555-563.
144. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog 2006, 2:e5.
145. Fischetti VA Streptococcal M protein extracted by nonionic detergent. II. Analysis of the antibody response to the multiple antigenic determinants of the M-protein molecule. J Exp Med 1977, 146:1108-1123.
146. Beres SB, Sylva GL, Barbian KD, et al. Genome sequence of a serotype M3 strain of group A streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci USA 2002, 99:10078-10083.
147. Tyrrell GJ, Lovgren M, Forwick B, Hoe NP, Musser JM, Talbot JA M types of group a streptococcal isolates submitted to the National Centre for Streptococcus (Canada) from 1993 to 1999. J Clin Microbiol 2002, 40:4466-4471.
148. Herwald H, Cramer H, Mörgelin M, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 2004, 116:367-379.
149. Sierig G, Cywes C, Wessels MR, Ashbaugh CD Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci. Infect Immun 2003, 71:446-455.
150. Dale JB, Washburn RG, Marques MB, Wessels MR Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun 1996, 64:1495-1501.
151. Kurupati P, Turner CE, Tziona I, et al. Chemokine-cleaving Streptococcus pyogenes protease SpyCEP is necessary and sufficient for bacterial dissemination within soft tissues and the respiratory tract. Mol Microbiol 2010, 76:1387-1397.
152. Olsen RJ, Sitkiewicz I, Ayeras AA, et al. Decreased necrotizing fasciitis capacity caused by a single nucleotide mutation that alters a multiple gene virulence axis. Proc Natl Acad Sci USA 2010, 107:888-893.
153. Nordenfelt P, Waldemarson S, Linder A, et al. Antibody orientation at bacterial surfaces is related to invasive infection. J Exp Med 2012, 209:2367-2381.
154. Seki M, Saito M, Iida K, et al. Onset of streptococcal toxic shock syndrome is accelerated by bruising in a mouse model. Microb Pathog 2008, 44:339-343.
155. Bryant AE, Bayer CR, Huntington JD, Stevens DL Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. J Infect Dis 2006, 193:1685-1692.
156. Hamilton SM, Bayer CR, Stevens DL, Lieber RL, Bryant AE Muscle injury, vimentin expression, and nonsteroidal anti-inflammatory drugs predispose to cryptic group A streptococcal necrotizing infection. J Infect Dis 2008, 198:1692-1698.
157. Kotloff KL, Dale JB Progress in group A streptococcal vaccine development. Pediatr Infect Dis J 2004, 23:765-766.
158. Dale JB, Penfound TA, Tamboura B, et al. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine 2013, 31:1576-1581.
159. Dale JB, Simmons M, Chiang EC, Chiang EY Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine 1996, 14:944-948.
160. Turner CE, Kurupati P, Wiles S, Edwards RJ, Sriskandan S Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi. Vaccine 2009, 27:4923-4929.
161. Cleary PP, Matsuka YV, Huynh T, Lam H, Olmsted SB Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine 2004, 22:4332-4341.